Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 14, 2013, Pages

  Knight, Jennifer F ^a   Lesurf, Robert ^a,b   Zhao, Hong ^a   Pinnaduwage, Dushanthi ^c   Davis, Ryan R ^d   Saleh, Sadiq M I ^a,b   Zuo, Dongmei ^a   Naujokas, Monica A ^a   Chughtai, Naila ^a   Herschkowitz, Jason I ^e   Prat, Aleix ^f,g   Mulligan, Anna Marie ^h,i   Muller, William J ^a,b   Cardiff, Robert D ^d   Gregg, Jeff P ^d   Andrulis, Irene L ^c,h,i   Hallett, Michael T ^a   Park, Morag ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^h ST MICHAEL'S HOSPITAL   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

EMT; Gene expression; Met RTK; Mouse model

Indexed keywords

CLAUDIN; MICRORNA; PROTEIN P53; SCATTER FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CELL GROWTH; CELL JUNCTION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE LOSS; GENE MUTATION; HUMAN; IN VIVO STUDY; MESENCHYME CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; BREAST NEOPLASMS; CELLS, CULTURED; CLAUDINS; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MICROARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE; MUS;

EID: 84875837439     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1210353110     Document Type: Article

References (56)

1. Ferlay et al. (2008) Globocan 2008 v2.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase 10. Available at https://globocan.iarc.fr.
2. Sørlie T, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874.
3. Herschkowitz JI, et al. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76.
4. Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 23(29):7350-7360.
5. Sorlie T, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418-8423.
6. Prat A, et al. (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12(5):R68.
7. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915-925.
8. Ponzo MG, Park M (2010) The Met receptor tyrosine kinase and basal breast cancer. Cell Cycle 9(6):1043-1050.
9. Camp RL, Rimm EB, Rimm DL (1999) Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86(11): 2259-2265.
10. Garcia S, et al. (2007) Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 38(6):830-841.
11. Ghoussoub RA, et al. (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82(8):1513-1520.
12. Taniguchi T, et al. (1995) Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1(9):1031-1034.
13. Tyan SW, et al. (2011) Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS ONE 6(1):e15313.
14. Ponzo MG, et al. (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 106(31):12903-12908.
15. Graveel CR, et al. (2009) Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 106(31): 12909-12914.
16. Smolen GA, et al. (2006) Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res 66(7):3452-3455.
17. He L, et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447(7148):1130-1134.
18. Perou CM, et al. (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752.
19. Lim E, et al.; kConFab (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15(8): 907-913.
20. Cardiff RD (2010) The pathology of EMT in mouse mammary tumorigenesis. J Mammary Gland Biol Neoplasia 15(2):225-233.
21. Jonkers J, et al. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29(4):418-425.
22. Junttila MR, Evan GI (2009) p53-a Jack of all trades but master of none. Nat Rev Cancer 9(11):821-829.
23. Weigman VJ, et al. (2012) Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat 133(3):865-880.
24. White DE, Cardiff RD, Dedhar S, Muller WJ (2001) Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 20(48):7064-7072.
25. Taube JH, et al. (2010) Core epithelial-to-mesenchymal transition interactome geneexpression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 107(35):15449-15454.
26. Kitamura T, Taketo MM (2007) Keeping out the bad guys: Gateway to cellular target therapy. Cancer Res 67(21):10099-10102.
27. Groom JR, Luster AD (2011) CXCR3 ligands: Redundant, collaborative and antagonistic functions. Immunol Cell Biol 89(2):207-215.
28. Matzke A, et al. (2007)Haploinsufficiency of c-Met in cd44-/- mice identifies a collaboration of CD44 and c-Met in vivo. Mol Cell Biol 27(24):8797-8806.
29. Gambarotta G, et al. (1996) Ets up-regulates MET transcription. Oncogene 13(9): 1911-1917.
30. Finkbeiner MR, et al. (2009) Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 28(11):1421-1431.
31. Blenkiron C, et al. (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8(10):R214.
32. Iorio MV, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065-7070.
33. Buffa FM, et al. (2011) microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 71(17):5635-5645.
34. Chang CJ, et al. (2011) p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13(3):317-323.
35. Kim T, et al. (2011) p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 208(5):875-883.
36. Gregory PA, et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10(5):593-601.
37. Sedeh RS, et al. (2010) Structure, evolutionary conservation, and conformational dynamics of Homo sapiens fascin-1, an F-actin crosslinking protein. J Mol Biol 400(3):589-604.
38. Nürnberg A, Kitzing T, Grosse R (2011) Nucleating actin for invasion. Nat Rev Cancer 11(3):177-187.
39. Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA (2009) Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev 23(22):2592-2597.
40. Mohammed RA, et al. (2007) Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 96(7):1092-1100.
41. Stratford AL, et al. (2007) Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basallike breast cancer, providing a potential target for therapy. Breast Cancer Res 9(5):R61.
42. Goodale D, Phay C, Postenka CO, Keeney M, Allan AL (2009) Characterization of tumor cell dissemination patterns in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry. Cytometry A 75(4):344-355.
43. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS (2011) Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 11(2):135-141.
44. Du YC, Chou CK, Klimstra DS, Varmus H (2011) Receptor for hyaluronan-mediated motility isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis and a tail vein assay for metastasis. Proc Natl Acad Sci USA 108(40): 16753-16758.
45. Ozcelik H, Pinnaduwage D, Bull SB, Andrulis IL (2007) Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer. Breast Cancer Res Treat 105(3):255-265.
46. Mulligan AM, Pinnaduwage D, Bull SB, O'Malley FP, Andrulis IL (2008) Prognostic effect of basal-like breast cancers is time dependent: Evidence from tissue microarray studies on a lymph node-negative cohort. Clin Cancer Res 14(13):4168-4174.
47. Voduc KD, et al. (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684-1691.
48. Curtis C, et al.; METABRIC Group (2012) The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486(7403):346-352.
49. Lehmann BD, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750-2767.
50. Herschkowitz JI, et al. (2012) Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci USA 109(8):2778-2783.
51. Xu K, et al. (2012) Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell 21(5):626-641.
52. Furuse M (2010) Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol 2(1):a002907.
53. Zöller M(2011) CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11(4):254-267.
54. Jeffers M, Rong S, Vande Woude GF (1996) Enhanced tumorigenicity and invasionmetastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16(3): 1115-1125.
55. Andrechek ER, et al. (2000) Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA 97(7):3444-3449.
56. Ling C, Zuo D, Xue B, Muthuswamy S, Muller WJ (2010) A novel role for 14-3-3sigma in regulating epithelial cell polarity. Genes Dev 24(9):947-956.